Published in Vaccine Weekly, November 23rd, 2005
"Induction of an immune response to amyloid-beta protein (A-beta) is effective in treating animal models of Alzheimer disease. Human clinical trials of vaccination with synthetic A-beta (ANI 792), however, were halted due to brain inflammation, presumably induced by T cell-mediated immune responses. We have developed an adenovirus vector as a 'possibly safer' vaccine. Here, we show that an adenovirus vector encoding 11 tandem repeats of A-beta 1-6 can induce an immune response against amyloid beta-protein," researchers in the United States report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.